ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform

Time: 9:00 am
day: Day Two

Details:

  • Examining how site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies
  • Demonstrating a novel method of affinity peptide mediated regiodivergent antibody functionalisation that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner
  • Highlighting how both thiol-based and azide-based site-specific ADCs produced by “AJICAP” technology demonstrated an expansion of their therapeutic index compared with stochastic technology

Speakers: